{
    "clinical_study": {
        "@rank": "116234", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients\n      who have metastatic kidney cancer."
        }, 
        "brief_title": "Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer", 
        "completion_date": {
            "#text": "July 2001", 
            "@type": "Actual"
        }, 
        "condition": "Kidney Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Evaluate the efficacy of arsenic trioxide in patients with metastatic renal\n      cell cancer. II. Determine the safety of this regimen in this patient population.\n\n      OUTLINE: Patients receive arsenic trioxide IV over 1-4 hours daily for 5 days. Treatment\n      continues every 4 weeks for a maximum of 12 courses in the absence of disease progression or\n      unacceptable toxicity. Patients are followed for at least 1 month.\n\n      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed metastatic renal cell cancer\n        Bidimensionally measurable disease No brain metastases\n\n        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Life\n        expectancy: Greater than 3 months Hematopoietic: WBC at least 3,000/mm3 Absolute\n        neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin\n        normal ALT or AST no greater than 2.5 times upper limit of normal (ULN) Renal: Creatinine\n        no greater than 1.5 times ULN (no greater than 1.95 mg/dL at MSKCC) Other: Not pregnant or\n        nursing Negative pregnancy test Fertile patients must use effective contraception during\n        and for 4 months after study No other prior malignancy unless curatively treated and\n        disease free for the past 5 years and considered low risk for recurrence\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy\n        and recovered No concurrent biologic therapy Chemotherapy: At least 4 weeks since prior\n        cytotoxic chemotherapy and recovered No other concurrent cytotoxic chemotherapy Endocrine\n        therapy: At least 4 weeks since prior hormonal therapy and recovered No concurrent\n        hormonal therapy Radiotherapy: At least 4 weeks since prior radiotherapy No concurrent\n        radiotherapy Surgery: At least 4 weeks since prior major surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "April 6, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005069", 
            "org_study_id": "99-107", 
            "secondary_id": [
                "CDR0000067674", 
                "NCI-T99-0105"
            ]
        }, 
        "intervention": {
            "intervention_name": "arsenic trioxide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Arsenic trioxide"
        }, 
        "keyword": [
            "stage IV renal cell cancer", 
            "recurrent renal cell cancer"
        ], 
        "lastchanged_date": "June 18, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-99107"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Trial of Arsenic Trioxide (NSC #706363) in Patients With Advanced Renal Cell Carcinoma", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Robert J. Motzer, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005069"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}